1. A Phase II Trial of Older Adults With Metastatic Breast Cancer Receiving nab-Paclitaxel: Melding the Fields of Geriatrics and Oncology
- Author
-
Enrique Soto-Perez-de-Celis, Joanne E. Mortimer, Arnold Rotter, Yuan Yuan, Daneng Li, Christina Yeon, Suzette Blanchard, Rachel Morrison, Vani Katheria, Nimit Sudan, Samuel Chung, J Waisman, Arti Hurria, Jennifer Choi, Ty Lee, Abrahm Levi, Thehang H. Luu, G. Somlo, Anne M. Noonan, Peggy Burhenn, Andrea Rubalcava, and Anait Arsenyan
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Paclitaxel ,Phases of clinical research ,Breast Neoplasms ,Article ,Drug Administration Schedule ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Albumins ,Internal medicine ,medicine ,Humans ,Neoplasm Metastasis ,Geriatric Assessment ,Aged ,Aged, 80 and over ,Geriatrics ,Framingham Risk Score ,business.industry ,Odds ratio ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Metastatic breast cancer ,Confidence interval ,Treatment Outcome ,030104 developmental biology ,Tolerability ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Introduction Phase II clinical trials including geriatric assessment (GA) measures are critical for improving the evidence base for older adults with cancer. We assessed the efficacy and tolerability of nab-paclitaxel in older adults with metastatic breast cancer (MBC). Patients and Methods Patients aged ≥ 65 years with MBC and ≤ 1 previous line of chemotherapy received 100 mg of nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle. A GA was completed pre-chemotherapy, and the validated Cancer and Aging Research Group (CARG) chemotherapy toxicity risk score was calculated. Relationships between tolerability (number of courses, hospitalizations, dose reductions, and toxicity) and risk score were assessed using general linear models, Student t tests, and the Fisher test. Response rate and progression-free survival were evaluated using the Kaplan-Meier method. Results Forty patients (mean age, 73 years; range, 65-87 years) were included. The median number of cycles was 6, 75% (n = 30) of patients had ≥ 1 dose hold, and 50% (n = 20) had ≥ 1 dose reduction. Fifty-eight percent (n = 23) had treatment-related ≥ grade 3 toxicities, and 30% (n = 12) were hospitalized owing to toxicity. Thirty-five percent (n = 14) responded, and the median progression-free survival was 6.5 months (95% confidence interval, 5.5 months to undefined). Patients with intermediate/high toxicity risk scores had higher risk of grade ≥ 3 toxicity than those with low risk scores (odds ratio, 5.8; 95% confidence interval, 1.3-33.1; P = .01). A higher mean risk score was associated with higher likelihood of dose reductions and hospitalizations. Conclusions Among older adults with MBC receiving weekly nab-paclitaxel, more than one-half experienced ≥ grade 3 chemotherapy toxicity. However, a GA-based risk score could predict treatment tolerability.
- Published
- 2019
- Full Text
- View/download PDF